Mitochondrial Function Test
December 3, 2019
This technology demonstrates a significant difference between ME / CFS patients and healthy controls.
Copyright © 2025 Open Medicine Foundation. All Rights Reserved.
This technology demonstrates a significant difference between ME / CFS patients and healthy controls.
This could be a very inexpensive and effective diagnostic test for ME/CFS.
The technology will be optimized for easy clinical adoption and scaled up so that numerous FDA-approved drugs can be simultaneously screened as potential treatments.
Throughout his career, Dr. Davis has conducted cutting edge, innovative, interdisciplinary research and technology development on cancer, immunology, genetics, infectious disease, novel drug development, and
Proteomic and Metabolic Plasma iCPET Studies By Ronald G.Tompkins, MD, ScD We have received an anonymous grant of $350,000 designated for the “Proteomic and Metabolomic
The goal of this study was to extend the Severely ill Patient Study and conduct a comprehensive “Big Data” analysis on ME/CFS patients and their families.
OMF is a non-profit 501(c)(3) organization
(EIN# 26-4712664). All donations are tax-deductible to the extent allowed by law.
Open Medicine Foundation®
29302 Laro Drive, Agoura Hills, CA 91301 USA
Phone: 650-242-8669
info@omf.ngo
Copyright © 2025 Open Medicine Foundation. All Rights Reserved.